Qais Alefan, Rana Azmi and Nizar Mhaidat
Jordan University of Science & Technology, Jordan
Posters & Accepted Abstracts: J Cancer Sci Ther
Colorectal cancer (CRC) includes cancerous growths in the colon and rectum. In Jordan, CRC is the most common cancer in men and the second in women. Health care systems all over the world are struggling with the dilemma of limited resources and growing needs. Estimates of the costs associated with CRC care are essential both for assessing burden of the disease at the population level and for conducting economic evaluations of interventions to prevent, detect, or treat CRC. This study estimated and analyzed the direct medical costs attributable to CRC in Jordan. A retrospective analysis of a cohort of patients treated for CRC data has been performed to determine the direct medical costs attributable to CRC in Jordan. Total CRC cancer cost in the year 2014 in KAUH was estimated to be JD 695,608. And the most expensive stage for all sites is stage 4 reaching a cost of JD 518,894. Statistically significant differences between stages costs were found (p<0.05). Advanced disease stages were associated with an increase in total cost, chemotherapy costs, and a decrease in surgical costs. Most of the total cost of the disease was attributable to drugs (chemotherapy mainly) then laboratory tests and follow up procedures. CRC creates an economic burden on health care services and more effort should be done for more awareness of CRC since most of the patients were presented in the advanced stage. The earlier the stage the less is the cost.
Qais Alefan has completed his PhD from Universiti Sains Malaysia. He is the Assistant Dean at Faculty of Pharmacy, JUST. He is a Member in the Drug Pricing Committee, JFDA, Jordan. He has published several papers in reputed journals and has been serving as an Editorial Board Member of repute.
Email: qmefan@just.edu.jo
Cancer Science & Therapy received 3968 citations as per Google Scholar report